Elucidation of the c-Jun N-Terminal Kinase Pathway Mediated by Epstein-Barr Virus-Encoded Latent Membrane Protein 1

REFERENCES

• Adachi, O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., and Akira S.. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL- 18-mediated function. Immunity 9:143–150.
   PubMed Web of Science ®Google Scholar
• Bradley, J. R., and Pober J. S.. 2001. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20:6482–6491.
   PubMedGoogle Scholar
• Cao, Z., Xiong J., Takeuchi M., Kurama T., and Goeddel D. V.. 1996. TRAF6 is a signal transducer for interleukin-1. Nature 383:443–446.
   PubMed Web of Science ®Google Scholar
• Chan, B. C., To K. F., Pang J. C., Chung Y. F., Lo K. W., Tong J. H., Huang D. W., Lim P. L., and Chui Y. L.. 2002. Generation of monoclonal antibodies against Hong Kong nasopharyngeal carcinoma-associated Epstein-Barr virus latent membrane protein 1 (LMP1). Int. J. Cancer 102:492–498.
   PubMedGoogle Scholar
• Chen, G., and Goeddel D. V.. 2002. TNF-R1 signaling: a beautiful pathway. Science 296:1634–1635.
   PubMed Web of Science ®Google Scholar
• Chen, W., White M. A., and Cobb M. H.. 2002. Stimulus-specific requirements for MAP3 kinases in activating the JNK pathway. J. Biol. Chem. 277:49105–49110.
   PubMed Web of Science ®Google Scholar
• Cheung, S. T., Leung S. F., Lo K. W., Chiu K. W., Tam J. S., Fok T. F., Johnson P. J., Lee J. C., and Huang D. P.. 1998. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. Int. J. Cancer 76:399–406.
   PubMedGoogle Scholar
• Cheung, S. T., Lo K. W., Leung S. F., Chan W. Y., Choi P. H., Johnson P. J., Lee J. C., and Huang D. P.. 1996. Prevalence of LMP1 deletion variant of Epstein-Barr virus in nasopharyngeal carcinoma and gastric tumors in Hong Kong. Int. J. Cancer 66:711–712.
   PubMed Web of Science ®Google Scholar
• Chung, J. Y., Park Y. C., Ye H., and Wu H.. 2002. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 115:679–688.
   PubMed Web of Science ®Google Scholar
• Davis, R. J. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103:239–252.
   PubMed Web of Science ®Google Scholar
• Devin, A., Lin Y., and Liu Z. G.. 2003. The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep. 4:623–627.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A. G., Blake S. M., Floettmann J. E., Rowe M., and Young L. S.. 1999. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 73:1023–1035.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A. G., Gallagher N. J., Blake S. M., Dawson C. W., and Young L. S.. 1999. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem. 274:16085–16096.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A. G., and Young L. S.. 1998. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein- Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731–1742.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A. G., and Young L. S.. 2001. LMP1 structure and signal transduction. Semin. Cancer Biol. 11:435–444.
   PubMed Web of Science ®Google Scholar
• Ghosh, S., and Karin M.. 2002. Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl.):S81–S96.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou, E., Miller W. E., Raab-Traub N., Kieff E., and Mosialos G.. 1998. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J. Immunol. 160:1116–1121.
   PubMedGoogle Scholar
• Hirschfeld, M., Ma Y., Weis J. H., Vogel S. N., and Weis J. J.. 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J. Immunol. 165:618–622.
   PubMed Web of Science ®Google Scholar
• Hoshino, K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., and Akira S.. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749–3752.
   PubMed Web of Science ®Google Scholar
• Izumi, K. M., and Kieff E. D.. 1997. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc. Natl. Acad. Sci. USA 94:12592–12597.
   PubMed Web of Science ®Google Scholar
• Janssens, S., and Beyaert R.. 2003. Functional diversity and regulation of different interleukin-1 receptor- associated kinase (IRAK) family members. Mol. Cell 11:293–302.
   PubMed Web of Science ®Google Scholar
• Jiang, Z., Ninomiya-Tsuji J., Qian Y., Matsumoto K., and Li X.. 2002. Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol. Cell. Biol. 22:7158–7167.
   PubMedGoogle Scholar
• Kaye, K. M., Izumi K. M., and Kieff E.. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B- lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150–9154.
   PubMed Web of Science ®Google Scholar
• Kieser, A., Kaiser C., and Hammerschmidt W.. 1999. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J. 18:2511–2521.
   PubMedGoogle Scholar
• Kieser, A., Kilger E., Gires O., Ueffing M., Kolch W., and Hammerschmidt W.. 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16:6478–6485.
   PubMed Web of Science ®Google Scholar
• Komatsu, Y., Shibuya H., Takeda N., Ninomiya-Tsuji J., Yasui T., Miyado K., Sekimoto T., Ueno N., Matsumoto K., and Yamada G.. 2002. Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis. Mech. Dev. 119:239–249.
   PubMed Web of Science ®Google Scholar
• Kulwichit, W., Edwards R. H., Davenport E. M., Baskar J. F., Godfrey V., and Raab-Traub N.. 1998. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA 95:11963–11968.
   PubMed Web of Science ®Google Scholar
• Lee, A. W., Foo W., Mang O., Sze W. M., Chappell R., Lau W. H., and Ko W. M.. 2003. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int. J. Cancer 103:680–685.
   PubMed Web of Science ®Google Scholar
• Liebowitz, D., Wang D., and Kieff E.. 1986. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J. Virol. 58:233–237.
   PubMed Web of Science ®Google Scholar
• Liu, Z. G., Hsu H., Goeddel D. V., and Karin M.. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87:565–576.
   PubMed Web of Science ®Google Scholar
• Mosialos, G. 2001. Cytokine signaling and Epstein-Barr virus-mediated cell transformation. Cytokine Growth Factor Rev. 12:259–270.
   PubMedGoogle Scholar
• Natoli, G., Costanzo A., Ianni A., Templeton D. J., Woodgett J. R., Balsano C., and Levrero M.. 1997. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2- dependent pathway. Science 275:200–203.
   PubMed Web of Science ®Google Scholar
• Ninomiya-Tsuji, J., Kishimoto K., Hiyama A., Inoue J., Cao Z., and Matsumoto K.. 1999. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398:252–256.
   PubMed Web of Science ®Google Scholar
• Nishitoh, H., Saitoh M., Mochida Y., Takeda K., Nakano H., Rothe M., Miyazono K., and Ichijo H.. 1998. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol. Cell 2:389–395.
   PubMed Web of Science ®Google Scholar
• Sanjo, H., Takeda K., Tsujimura T., Ninomiya-Tsuji J., Matsumoto K., and Akira S.. 2003. TAB2 is essential for prevention of apoptosis in fetal liver but not for interleukin-1 signaling. Mol. Cell. Biol. 23:1231–1238.
   PubMed Web of Science ®Google Scholar
• Schultheiss, U., Puschner S., Kremmer E., Mak T. W., Engelmann H., Hammerschmidt W., and Kieser A.. 2001. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J. 20:5678–5691.
   PubMedGoogle Scholar
• Schwandner, R., Yamaguchi K., and Cao Z.. 2000. Requirement of tumor necrosis factor receptor-associated factor (TRAF) 6 in interleukin 17 signal transduction. J. Exp. Med. 191:1233–1240.
   PubMed Web of Science ®Google Scholar
• Shibuya, H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., Irie K., Nishida E., and Matsumoto K.. 1996. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272:1179–1182.
   PubMed Web of Science ®Google Scholar
• Suzuki, N., Suzuki S., Duncan G. S., Millar D. G., Wada T., Mirtsos C., Takada H., Wakeham A., Itie A., Li S., Penninger J. M., Wesche H., Ohashi P. S., Mak T. W., and Yeh W. C.. 2002. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416:750–756.
   PubMed Web of Science ®Google Scholar
• Takaesu, G., Kishida S., Hiyama A., Yamaguchi K., Shibuya H., Irie K., Ninomiya-Tsuji J., and Matsumoto K.. 2000. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 5:649–658.
   PubMed Web of Science ®Google Scholar
• Takaesu, G., Surabhi R. M., Park K. J., Ninomiya-Tsuji J., Matsumoto K., and Gaynor R. B.. 2003. TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J. Mol. Biol. 326:105–115.
   PubMed Web of Science ®Google Scholar
• Wang, C., Deng L., Hong M., Akkaraju G. R., Inoue J., and Chen Z. J.. 2001. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346–351.
   PubMed Web of Science ®Google Scholar
• Wang, D., Liebowitz D., and Kieff E.. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 43:831–840.
   PubMed Web of Science ®Google Scholar
• Wu, Z., Wu J., Jacinto E., and Karin M.. 1997. Molecular cloning and characterization of human JNKK2, a novel Jun NH2-terminal kinase-specific kinase. Mol. Cell. Biol. 17:7407–7416.
   PubMed Web of Science ®Google Scholar
• Ye, H., Arron J. R., Lamothe B., Cirilli M., Kobayashi T., Shevde N. K., Segal D., Dzivenu O. K., Vologodskaia M., Yim M., Du K., Singh S., Pike J. W., Darnay B. G., Choi Y., and Wu H.. 2002. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418:443–447.
   PubMed Web of Science ®Google Scholar
• Yeh, W. C., Shahinian A., Speiser D., Kraunus J., Billia F., Wakeham A., de la Pompa J. L., Ferrick D., Hum B., Iscove N., Ohashi P., Rothe M., Goeddel D. V., and Mak T. W.. 1997. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7:715–725.
   PubMed Web of Science ®Google Scholar